ReviewBJU international2017
Guideline of guidelines: non-muscle-invasive bladder cancer.
Review in BJU international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03254888 (Identification of Novel Autophagy Markers in Bladder Cancer Patients), which is not on this map. Cited by 141 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identification of Novel Autophagy Markers in Bladder Cancer Patients
Who cites it
141 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Optimal energy source selection strategies for en bloc resection in non-muscle invasive bladder cancer: a systematic review and network meta-analysis.World journal of urology · 2025Pooled it
- Diagnostic Performance and Interobserver Agreement of the Vesical Imaging-Reporting and Data System (VI-RADS) in Bladder Cancer Staging: A Systematic Review.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Diagnostic accuracy of cytology and urine methylation test in patients with non-muscle invasive bladder cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Dietary consumption of cruciferous vegetables and bladder cancer risk: A systematic review and meta-analysis.Frontiers in nutrition · 2022Pooled it
- The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta-analysis.Journal of clinical laboratory analysis · 2021Pooled it
- Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors: A PRISMA-compliant meta-analysis.Medicine · 2019Pooled it
- Combination of Intravesical Bacille Calmette-Guérin and Chemotherapy vs. Bacille Calmette-Guérin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review.BMJ open · 2018Pooled it
- Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT.Health technology assessment (Winchester, England) · 2024Trial
- Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer.BMC urology · 2023Trial
- Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.Journal of cancer research and clinical oncology · 2019Trial
- Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy.Investigative and clinical urology · 2018Trial
- KRT14 activated by transcription factor E2F1 promotes bladder cancer progression.Oncology letters · 2026Article
- Squamoid and glycogen-rich-like clear-cell change in low-grade papillary urothelial carcinoma: a clinicopathologic analysis.Virchows Archiv : an international journal of pathology · 2026Article
- Article
- FDA approval of mitomycin hydrogel (Zusduri): a new non-surgical era for non-muscle-invasive bladder cancer (NMIBC).Annals of medicine and surgery (2012) · 2026Article
- CystoDS: a multiclass endoscopy image dataset for artificial intelligence-assisted bladder cancer detection.Scientific data · 2026Article
- High Oncological Efficacy of BCG Maintenance Therapy for Primary High-Grade T1 Urothelial Carcinoma of the Bladder.Cancers · 2026Article
- Multidimensional liquid biopsy in bladder cancer: advances in circulating tumor cells, circulating tumor DNA, exosomes, and metabolomics.The oncologist · 2026Review
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Non-muscle-invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, but this definition represents a spectrum of disease with a variable clinical course, notable for significant risk of recurrence and potential for progression. Management involves risk-adapted strategies of cystoscopic surveillance and intravesical therapy with the goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, but adherence to management principles among practising urologists is reportedly low. We review four major organizational guidelines on NMIBC: the American Urological Association (AUA)/Society of Urologic Oncology (SUO), European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), and National Institute for Health and Care Excellence (NICE) guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.